Acne 

Actinic Keratosis 

Aesthetics

Alopecia

Biologic Treatments for Moderate to Severe Atopic Dermatitis 

Atopic Dermatitis 

COVID-19

Chronic Hand Eczema

Drug Watch

Eczema

General Dermatology 

Hidradenitis Suppurativa

Melasma

NP and PA

Pediatric Dermatology

Pigmentary Disorders 

Practice Management 

Precision Medicine and Biologics

Prurigo Nodularis

Emerging Therapies Plaque Psoriasis

Treatments for Plaque Psoriasis 

Psoriasis 

Psoriatic Arthritis 

Rare Disease

Rosacea 

Skin Cancer (Nonmelanoma)

Skin Cancer

Vitiligo

Wound Care

News

Media

Around the Practice

Between The Lines

Case-Based Peer Perspective

Clinical Case Collective

DermView

Expert Perspectives

Fellows Face Off

Frontline Forum

Medical World News

Patient Perspectives

Podcasts

Readout360

Recognize and Refer

Conferences

Conference Coverage

Conference Listing

Events

Case-Based Roundtable

Publication

Dermatology Times

CME/CE

Resources

DermIQ

Interactive Tools

Job Board

Partner Perspectives

Perspectives in Dermatology

Polls

Editorial Advisory Board

Partners

Subscribe

Maddi Hebebrand is an associate editor of 

and joined the MJH Life Sciences team in May 2024. She attended Baldwin Wallace University, studying Media Production and Film, and is now finishing her Masters in Digital Media through Ohio University. When she's not writing, Maddi loves to read, attend concerts and spend time with her family.

Articles

Researchers found the TYK2 inhibitor deucravacitinib offers superior efficacy to apremilast and comparable outcomes to biologics.

Review Compares Psoriasis Therapies in Asian Populations

Review insights from a premier dermatology event with expert sessions, hands-on insights, and networking to elevate clinical practice.

Elevate-Derm West Conference 2024 Recap

and joined the MJH Life Sciences team in February 2023. She attended Kent State University and earned a Bachelor of Science degree in journalism with minors in public relations and creative writing. She enjoys making and listening to music, reading, and spending time with her cats, Astrid and Marceline.

The LIBERO study confirmed brodalumab is effective in managing psoriasis in patients over 100 kg, showing comparable long-term benefits in patients under 100 kg.

Subgroup Analysis Reveals Equal Benefit of Brodalumab in Obese vs Non-Obese Patients With Psoriasis

Kaitlyn Bader is the assistant managing editor of 

 and joined the MJH Life Sciences team in June 2022. She attended Otterbein University in Westerville, Ohio, and earned a Bachelor of Arts degree in literary studies with minors in creative writing and film studies. Prior to health care news, Kaitlyn worked in industrial marketing. She enjoys cooking, reading, and tending to her house plants.

Christopher Bunick, MD, PhD, discusses the multifactorial nature of chronic hand eczema, the burden of severe symptoms, and how delgocitinib restores skin integrity by targeting JAK/STAT pathways.

Reviewing Multiple Subtypes of CHE and Delgocitinib as a Pan-JAK Inhibitor

About

Advertise

Contact Us

Do Not Sell My Information

Terms and Conditions

Privacy Policy

Dermatology Times and Multimedia Medical, LLC

Facebook

Linkedin

Topics

Acne

Pigmentary Disorders

Practice Management

Psoriasis

Psoriatic Arthritis

Rosacea

1rem

Authors

Nivolumab plus talazoparib did not produce RECIST-based tumor responses in heavily pretreated patients with unresectable or metastatic melanoma.

Nivolumab Plus Talazoparib Does Not Induce Responses in Heavily Pretreated Melanoma

Final Thoughts: The Importance of Comparative Studies in AD

Panelists offer concluding insights and emphasize the critical role of comparative studies in advancing atopic dermatitis treatment strategies.

clinical

Video Series

Hyperhidrosis is not rare. According to the 

, approximately 385 million people worldwide live with hyperhidrosis.

In fact, they note that the amount of people living with chronic, excessive sweating is even higher than the amount of people living with other dermatologic conditions like psoriasis.

Just how common is hyperhidrosis in real-world comparisons?

The prevalence of hyperhidrosis is much higher in younger populations than in the general population, with 8.8% of individuals between the ages of 18 to 39 years old living with the condition. 

When comparing these statistics to everyday, common occurrences like hair color, the number of people with hyperhidrosis is greater than the 1% of individuals with natural red hair and 2% of individuals with natural blond hair. 

Despite how common hyperhidrosis is, it is estimated that 27% of those with the condition never receive a diagnosis.

 wants to hear from you. What percentage of the global population is estimated to have hyperhidrosis?

 to share your hyperhidrosis insights or research.

Albert. Fact check: Hyperhidrosis - International Hyperhidrosis Society: Official site. Home - International Hyperhidrosis Society. October 24, 1970. Accessed November 16, 2023. 

https://www.sweathelp.org/home/news-blog/542-fact-check-hyperhidrosis.html

Hyperhidrosis affects approximately 385 million people globally, surpassing the prevalence of other dermatologic conditions like psoriasis. It is notably more common in younger populations, with 8.8% of individuals aged 18 to 39 experiencing the condition. Comparatively, hyperhidrosis is more prevalent than natural red or blond hair, which affects 1% and 2% of the population, respectively. Despite its prevalence, 27% of those with hyperhidrosis remain undiagnosed. The article encourages engagement during Hyperhidrosis Awareness Month to share insights and research on the condition.

Click here to answer this week's poll for Hyperhidrosis Awareness Month.

Polls 

POLL: What Percent of the Global Population is Estimated to Have Hyperhidrosis?

Tiffany Mayo, MD, provides insights and practical tips in patient communication for the diagnosis and management of patients with hidradenitis suppurativa.

Hidradenitis Suppurativa: Practical Tips and Considerations Regarding Diagnosis, Treatment, and Patient Communication

Hi, and welcome to this Dermatology Times Partner Perspective video series. I’m Tiffany Mayo, associate professor, vice chair of diversity and inclusion, and director of the clinical research unit at the Heersink School of Medicine department of dermatology at the University of Alabama at Birmingham. In the first video, we discussed the clinical features, patient burden, and challenges of diagnosis of hidradenitis suppurativa, or HS. In this final video, I’ll wrap up the conversation with a few final thoughts.

This episode, "Hidradenitis Suppurativa: Practical Tips and Considerations Regarding Diagnosis, Treatment, and Patient Communication" is sponsored by Novartis, and I have been compensated for my time.

I mentioned in the first video that the average time of delay in HS diagnosis is 7 to 10 years.

 During this delay, patients see an average of 3 different providers and receive 3 misdiagnoses before receiving the correct diagnosis, which is typically given by a dermatologist.

 These are general statistics, but I can share here that most of my patients report similar real-world experiences. From the patient perspective, this delay causes frustration and distrust. From a disease management perspective, a delayed diagnosis can lead to greater difficulty in resolving HS symptoms and progression.

Upon diagnosis, it is important to name the condition and help the patient understand what it is and how and why it needs to be treated. Patients with HS frequently have questions that can culminate in a time-intensive visit, involving at least 30 minutes of extensive counseling and additional time for prior authorization of medications.

 It’s understandable that recurrent visits of this type may not be practical for all HCPs; however, we are all responsible for ensuring that patients are accurately diagnosed and are on the right track for optimal disease management. Collaborating with local HS experts or other physicians who can help manage the disease is key when this is the case. Because there can be a delay in access to these physicians, it is recommended to start patients on an initial regimen but inform them that they will require follow-up and, likely, treatment escalation that will be handled by a colleague you are able to name.

Resources are also available to help with patient education and disease management. Foundations such as the US and Canadian HS Foundations play an important role in educating patients and clinicians through symposiums and other efforts.

 There are many tools HCPs can find helpful, including prior authorization templates, treatment guidelines, and HS specialty clinic directories.

I would like to summarize this video series by reiterating HS is a chronic, painful disease with a substantial impact on patient quality of life. There is typically a delay in time to accurate diagnosis and the disease is often suboptimally managed. Though more work is needed, we can support our patients by helping them understand the disease and by appropriately managing it. Thank you to our viewers for watching.

 HS Foundation. Accessed May 6, 2024. https://www.hs-foundation.org/

Hidradenitis suppurativa (HS) is a chronic, painful condition with significant patient impact, often experiencing diagnostic delays of 7-10 years. Patients typically see multiple providers and receive misdiagnoses before a dermatologist correctly identifies HS. Effective management requires clear communication, patient education, and collaboration with HS specialists. Initial treatment regimens should be started promptly, with plans for follow-up and potential treatment escalation. Resources like the US and Canadian HS Foundations provide valuable support for both patients and healthcare providers, aiding in education and disease management.

 (HSF) offers a range of grant opportunities designed to advance research and clinical expertise in hidradenitis suppurativa (HS). These grants aim to support researchers at different career stages, from early investigators to established practitioners, by providing funding to develop new treatment insights, improve patient care, and stimulate innovative, translational research. Below is an overview of the available grants:

 This grant seeks to promote clinical and translational research projects that can meaningfully improve patient care in the field of HS. Researchers are invited to submit applications that propose new approaches to understanding HS, including studies on disease mechanisms, therapeutic strategies, or patient-centered care models. Award amounts range from $5,000 to $20,000, allowing researchers flexibility to design studies that fit their project scope. A minimum of five grants may be awarded annually, subject to funding availability. This grant is ideal for early-stage investigators, as priority is given to applicants who are new to HS research. 

 Aimed at encouraging novel research capable of attracting long-term funding from the National Institutes of Health (NIH) or similar agencies, this grant supports innovative approaches in HS research. Eligible researchers can apply for up to $75,000 to fund one-year projects. The goal is to bridge the gap between basic science and clinical practice, enabling researchers to conduct studies that have the potential to translate directly into improved patient outcomes. Applications are welcome from early-stage investigators and collaborative research teams within an institution. 

 This grant supports trainees and early-career faculty interested in gaining hands-on experience in managing HS under the guidance of an established HS expert. The award provides up to $4,000 to fund up to four weeks of mentored clinical practice and procedural training. This unique opportunity aims to nurture the next generation of HS specialists by creating pathways to learn from seasoned practitioners and enhance skills in clinical care, research, and patient education. Priority is given to applicants from areas without access to an HS clinic.

All applicants will be notified of acceptance at the American Academy of Dermatology Annual Meeting in March 2025.

For more information on each grant and application instructions, please visit the respective links provided.

The Hidradenitis Suppurativa Foundation (HSF) offers grants to advance research and clinical expertise in hidradenitis suppurativa (HS). These grants support researchers at various career stages, from early investigators to established practitioners, aiming to develop new treatment insights, improve patient care, and stimulate innovative research. The Danby Research Grant focuses on clinical and translational projects, the Translational Research Grant encourages novel research with potential for long-term funding, and the Mentored Experience Grant provides hands-on experience for trainees. Application deadlines are in December 2024 and January 2025.

The Hidradenitis Suppurativa Foundation offers grants for HS research and clinical expertise, supporting early-stage to established investigators.

Grant Opportunities from the Hidradenitis Suppurativa Foundation: Supporting Innovation and Expertise in HS Research and Care

, symptoms of psoriasis often start between the ages of 15 and 25.

 However, symptoms of psoriasis can start at any age and stage of life.

The majority of patients with psoriasis will experience their first flare when they are between the ages of 15 and 35. Despite this, nearly 1 in 3 patients are under the age of 20 at the disease's first onset.

"While it can begin at any age, psoriasis has 2 peaks of onset, the first at age 20 to 30 years and the second at age 50 to 60 years," according to April Armstrong, MD, MPH.

 "It affects men and women equally but is more common in non-Hispanic whites. Some patients are more prone to developing psoriasis, especially if there is a family member with psoriasis."

Psoriasis: Causes, triggers and treatments. The National Psoriasis Foundation: National Psoriasis Foundation. Accessed August 4, 2023. 

https://www.psoriasis.org/about-psoriasis/

Psoriasis typically manifests between ages 15 and 35, with two onset peaks at 20-30 and 50-60 years. It affects men and women equally, predominantly in non-Hispanic whites. Approximately one-third of patients experience their first symptoms before age 20. Genetic predisposition plays a significant role, especially if a family member has psoriasis. The condition can begin at any age, highlighting the importance of awareness across all demographics. Understanding these patterns aids in early diagnosis and management, improving patient outcomes.

This Psoriasis Awareness Month, test your knowledge of the condition. Click here to answer this week's poll.

POLL: At What Age Do Symptoms of Psoriasis Often Start?

Dermatology physician associates took a break from learning and networking to give back to the community during the Society of Dermatology Physician Associates (SDPA) 2024 Fall Dermatology Conference in Las Vegas, Nevada, by volunteering with the Sun Bus.

PA clinician-volunteers at the Sun Bus, which was parked outside of the conference hotel, screening individuals for skin cancer and sun damage as well as educating interested individuals about sun dangers and sun protection in conjunction with the Sun Bus. The event was organized by the philanthropic arm of the SDPA, 

. DPAF hosted a similar sun cancer screening with the Sun Bus during the 2024 Society of Dermatology Physician Associates Summer Conference in San Diego, California, in June.

DPAF Sun Bus 

Established in 2015 to help dermatology PAs expand their leadership and contributions to the field of dermatology, the mission of the Dermatology PA Foundation (DPAF) is to “inspire and invest in Derm PAs to succeed in professional development and philanthropic service to impact communities and provide inclusion for all.” Faseeha Raza, MMS, PA-C, the current chair of the organization, is proud of its commitment to give back to the community and has encouraged the sense of volunteerism.

The Sun Bus, which was acquired in May 2019, comes courtesy of the Colorado Melanoma Foundation. Its goal is to deliver free skin checks and promote sun safety and skin cancer awareness.

about her role with DPAF. “My No. 1 goal would be to cause brand awareness, and letting people know why DPAF exists,” she told 

in an exclusive interview. “So my goal would be to promote our programming, such as Medical Mission Academy, talks in a box, professional development, and research. And knowing all these, I'm very confident a lot of PAs would be interested in becoming part of it and volunteer for it.”

Are you attending the 2024 SDPA Fall Conference? Share your impressions and highlights with your colleagues. Email DTEditor@mmhgroup.com

Dermatology physician associates participated in community service during the SDPA 2024 Fall Dermatology Conference by volunteering with the Sun Bus to provide skin cancer screenings and sun safety education. This initiative, organized by the Dermatology PA Foundation (DPAF), reflects its mission to enhance professional development and community impact. The Sun Bus, acquired from the Colorado Melanoma Foundation, aims to increase skin cancer awareness. Faseeha Raza, chair of DPAF, emphasizes promoting the foundation's programs to encourage more PAs to engage in volunteerism and professional growth.

Dermatology physician associates via DPAF conduct skin checks at the Sun Bus during the Fall Conference. 

Ryan Scott

Articles

Latest Updated Articles